Pharmaceutical composition for nasal administration

A pharmaceutical composition and transnasal technology, applied in the directions of drug combination, drug delivery, and pharmaceutical formulation, can solve problems such as failure, achieve high drug efficacy, achieve non-invasive, and low side effects.

Pending Publication Date: 2020-02-21
MEDILABO RFP INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, most of them have failed clinically due to reasons such as unexpected side effects or failure to produce expected drug effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for nasal administration
  • Pharmaceutical composition for nasal administration
  • Pharmaceutical composition for nasal administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0062] Hereinafter, although an Example is shown and this invention is demonstrated more concretely, this invention is not limited to these Examples.

experiment example

[0064] In this experimental example, the administration composition containing rifampicin or not containing rifampicin was administered daily for one month to the mice shown in Table 1 at the dosage and usage shown in Table 1.

[0065] (administration object)

[0066] Preparation of 11-month-old male APP OSK Mice (Tomiyama et al. J Neurosci. 2010; 30:4845-56). app OSK The body weight of the mice is about 30 g. will APP OSK 60 mice were divided into 5 groups of 12 each. In addition, 12 wild-type mice (non-transgenic littermates (non-Tg littermate)) of the same age were prepared. It should be noted that APP OSK Mice are amyloid precursor protein (APP) transgenic mice (Alzheimer's disease model), showing accumulation of β-amyloid (Aβ).

[0067] (drug composition)

[0068] Rifampicin (RFP; Sigma-Aldrich, Rifampicin≥97% (HPLC), powder, alias: 3-(4-methylpiperazinyliminomethyl) rifamycin SV, rifamycin AMP , rifampicin, R3501) was suspended in 0.5w / v% carboxymethylcellulose ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the first pass to the liver. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to thebrain and suppressing the first pass to the liver.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for nasal administration, which has a high therapeutic effect and suppresses side effects, and is useful for the prevention or treatment of dementia. Background technique [0002] Dementia includes cerebrovascular dementia, which is caused by cerebrovascular disorders, and degenerative dementia, which is caused by abnormal protein accumulation in the brain. The latter have Alzheimer's disease (AD) with β-amyloid (Aβ) and tau accumulation, frontotemporal dementia (FTD) with tau or TDP-43 accumulation, Lewy syndrome with α-synuclein accumulation Dementia Body Disease (DLB), etc. It is thought that these proteins form oligomers in the brain and impair the function of nerve cells to cause the disease. Based on this idea, drugs that inhibit the production of these proteins, inhibit the formation of oligomers, and remove aggregated proteins from the brain are being developed as therapeutic drugs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P25/28
CPCA61K31/496A61P25/28A61K9/0043A61K9/10
Inventor 富山贵美梅田知宙
Owner MEDILABO RFP INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap